Abstract
Research consortia in Europe often compete with each other for skills, human and technical resources and, eventually, recognition of the scientific impact of their work. In response to the same EU Horizon2020 call, we received funding for our research project proposals to identify and validate novel drug targets for cardiovascular disease treatment. Each consortium followed a unique and independent research strategy. However, as coordinators of these consortia we envisioned we could increase impact, outcomes and efficiency by intensifying our interaction. At an agreed stage during our projects we chose to share our knowledge, vision and ideas. In this paper we present what we learned, in the hope that future consortia will see the benefits of this approach.
| Original language | English |
|---|---|
| Journal | Drug Discovery Today |
| Volume | 25 |
| Issue number | 4 |
| Pages (from-to) | 787-792 |
| Number of pages | 6 |
| ISSN | 1359-6446 |
| DOIs | |
| Publication status | Published - 04.2020 |
Funding
The authors would like to thank all the partners of the consortia for their contribution to the successful execution of the three projects as well as for their active participation in exchange of knowledge during the joint meeting of the consortia. The European Commission is gratefully acknowledged for the funding of the consortia through grant agreements no. 601456 CVgenes@Target , no. 603091 TransCard and no. 602936 CarTarDis ). The work by Heribert Schunkert and Jeanette Erdmann was also supported by grants from the Fondation Leducq ( CADgenomics : Understanding CAD Genes, 12CVD02), the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (e:AtheroSysMed, grant 01ZX1313A-2014; BlockCAD :16GW0198K, e:Med: AbCD-Net:01ZX1706C), Research-ERA-NET (ERA-CVD:JTC2017_21-040). Further grants were received from the DFG as part of the Sonderforschungsbereich CRC 1123 (B2).
Research Areas and Centers
- Research Area: Medical Genetics
